Addenbrooke's Cognitive Examination-Revised for mild cognitive impairment in Parkinson's disease§


  • Funding agencies: This work was supported by a National Institute for Health Research Biomedical Research Award to Addenbrooke's Hospital/University of Cambridge, as well as grants from Cure Parkinson's Trust and Parkinson's Disease UK. D.P.B., J.R.E., and C.H.W.G. have each been recipients of a Raymond and Beverly Sackler Studentship.

  • Relevant conflicts of interest/financial disclosures: Nothing to report.

  • §

    Full financial disclosures and author roles may be found in the online version of this article.



Cognitive impairment is common in Parkinson's disease (PD), even in the early stages, and appropriate screening tools are needed.


We investigated the utility of the Addenbrooke's Cognitive Examination-Revised for detecting mild cognitive impairment (MCI) in PD in an incident population-representative cohort (n = 132) and investigated the relationship between performance on this instrument and behavior and quality of life (n = 219).


Twenty-two percent met criteria for MCI. Receiver operating curve analysis revealed an area under the curve of 0.81. A cutoff <89 gave a sensitivity of 69% and specificity of 84%. Scores on this instrument were highly correlated with the Parkinson's Disease Cognitive Rating Scale, and there were significant correlations with the Cambridge Behavioral Inventory-Revised and Parkinson's Disease Questionnaire 39.


This instrument is a useful screening tool for PD-MCI, and poor performance is significantly related to impaired behavior and quality of life. © 2012 Movement Disorder Society